The latest update is out from Neurotech International Ltd. ( (AU:NTI) ).
Neurotech International Ltd. announced a change in the director’s interest, revealing that Director Anthony Filippis, through Antfilippis Investments Pty Ltd, acquired 10 million NTIOPT28 and 10 million NTIOPT29 unlisted options. These options, set to mature in 2030, were acquired at no cost. This acquisition of options reflects strategic positioning within the company, potentially enhancing the director’s influence in company decisions and aligning interests with future company performance.
More about Neurotech International Ltd.
Neurotech International Ltd. operates in the technology and healthcare industries, focusing on developing innovative neurotechnology solutions. The company primarily offers products and services aimed at enhancing cognitive function and mental well-being, targeting both clinical and consumer markets.
YTD Price Performance: -33.33%
Average Trading Volume: 608,728
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$41.68M
For an in-depth examination of NTI stock, go to TipRanks’ Stock Analysis page.